Estrella Immunopharma, Inc.
ESLA
$1.14
$0.010.89%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 891.80K | 587.80K | 648.50K | 883.70K | 694.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.29M | 613.20K | 4.80M | 5.54M | 2.10M |
| Operating Income | -2.29M | -613.20K | -4.80M | -5.54M | -2.10M |
| Income Before Tax | -2.29M | -613.20K | -4.80M | -5.54M | -2.10M |
| Income Tax Expenses | -- | 0.00 | -- | 900.00 | 0.00 |
| Earnings from Continuing Operations | -2.29M | -613.20K | -4.80M | -5.54M | -2.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.29M | -613.20K | -4.80M | -5.54M | -2.10M |
| EBIT | -2.29M | -613.20K | -4.80M | -5.54M | -2.10M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.05 | -0.02 | -0.13 | -0.15 | -0.06 |
| Normalized Basic EPS | -0.03 | -0.01 | -0.08 | -0.10 | -0.04 |
| EPS Diluted | -0.05 | -0.02 | -0.13 | -0.15 | -0.06 |
| Normalized Diluted EPS | -0.03 | -0.01 | -0.08 | -0.10 | -0.04 |
| Average Basic Shares Outstanding | 42.12M | 37.82M | 37.10M | 36.17M | 36.19M |
| Average Diluted Shares Outstanding | 42.12M | 37.82M | 37.10M | 36.17M | 36.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |